AU2008224962B2 - Intravesical apaziquone administration following transurethral resection for treating cancer - Google Patents

Intravesical apaziquone administration following transurethral resection for treating cancer Download PDF

Info

Publication number
AU2008224962B2
AU2008224962B2 AU2008224962A AU2008224962A AU2008224962B2 AU 2008224962 B2 AU2008224962 B2 AU 2008224962B2 AU 2008224962 A AU2008224962 A AU 2008224962A AU 2008224962 A AU2008224962 A AU 2008224962A AU 2008224962 B2 AU2008224962 B2 AU 2008224962B2
Authority
AU
Australia
Prior art keywords
apaziquone
tur
cancer
bladder
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008224962A
Other languages
English (en)
Other versions
AU2008224962A1 (en
Inventor
Mario Beer
Shanta Chawla
Luigi Lenaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spectrum Pharmaceuticals Inc
Original Assignee
Spectrum Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals Inc filed Critical Spectrum Pharmaceuticals Inc
Publication of AU2008224962A1 publication Critical patent/AU2008224962A1/en
Application granted granted Critical
Publication of AU2008224962B2 publication Critical patent/AU2008224962B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2008224962A 2007-03-13 2008-03-13 Intravesical apaziquone administration following transurethral resection for treating cancer Ceased AU2008224962B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89461007P 2007-03-13 2007-03-13
US60/894,610 2007-03-13
PCT/US2008/056912 WO2008112934A1 (en) 2007-03-13 2008-03-13 Intravesical apaziquone administration following transurethral resection for treating cancer

Publications (2)

Publication Number Publication Date
AU2008224962A1 AU2008224962A1 (en) 2008-09-18
AU2008224962B2 true AU2008224962B2 (en) 2013-07-25

Family

ID=39494173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008224962A Ceased AU2008224962B2 (en) 2007-03-13 2008-03-13 Intravesical apaziquone administration following transurethral resection for treating cancer

Country Status (17)

Country Link
US (1) US20080227841A1 (enExample)
EP (1) EP2134322B1 (enExample)
JP (2) JP5788143B2 (enExample)
KR (1) KR20090128479A (enExample)
CN (1) CN101677942B (enExample)
AR (1) AR065732A1 (enExample)
AU (1) AU2008224962B2 (enExample)
BR (1) BRPI0808804A2 (enExample)
CA (1) CA2680481C (enExample)
ES (1) ES2727257T3 (enExample)
IL (1) IL200899A0 (enExample)
MX (1) MX2009009777A (enExample)
NZ (1) NZ579609A (enExample)
RU (2) RU2480200C2 (enExample)
TW (1) TWI434684B (enExample)
WO (1) WO2008112934A1 (enExample)
ZA (1) ZA200906328B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201213486D0 (en) * 2012-07-30 2012-09-12 Univ Salford The Quinone compounds and their uses for the treatment of cancer
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) * 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2178305C1 (ru) * 2000-11-02 2002-01-20 Гарбер Александр Григорьевич Ирригационный раствор
RU2002121829A (ru) * 2002-08-07 2004-02-27 Сгму Способ лечения местнораспространенных форм рака мочевого пузыря

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) * 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer

Also Published As

Publication number Publication date
IL200899A0 (en) 2010-05-17
ZA200906328B (en) 2010-05-26
MX2009009777A (es) 2009-11-26
AR065732A1 (es) 2009-06-24
RU2623142C2 (ru) 2017-06-22
TWI434684B (zh) 2014-04-21
TW200904410A (en) 2009-02-01
NZ579609A (en) 2012-01-12
RU2480200C2 (ru) 2013-04-27
RU2009137770A (ru) 2011-04-20
KR20090128479A (ko) 2009-12-15
CA2680481C (en) 2016-06-21
CA2680481A1 (en) 2008-09-18
CN101677942A (zh) 2010-03-24
EP2134322A1 (en) 2009-12-23
BRPI0808804A2 (pt) 2014-08-19
EP2134322B1 (en) 2019-02-20
WO2008112934A1 (en) 2008-09-18
JP5788143B2 (ja) 2015-09-30
JP2010521488A (ja) 2010-06-24
ES2727257T3 (es) 2019-10-15
AU2008224962A1 (en) 2008-09-18
CN101677942B (zh) 2013-10-30
JP2014028841A (ja) 2014-02-13
RU2012157329A (ru) 2014-07-10
US20080227841A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
US8765729B2 (en) Cancer therapy
KR20210053948A (ko) 겸상 세포 질환의 치료를 위한 pde9 억제제
US20220323433A2 (en) Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor
US20150190413A1 (en) Compositions and methods for the treatment of bladder cancer
JP2000504020A (ja) ＨＥＲ２／ｎｅｕを過剰発現するガン細胞の化学療法剤に対する感作
CA2680481C (en) Intravesical apaziquone administration following transurethral resection for treating cancer
JP2004535396A (ja) アミホスチン及び関連化合物を用いる化学防御
KR20200051690A (ko) 국소 조성물
KR20200051689A (ko) 국소 조성물 및 치료 방법
Sweatman et al. Pharmacologic rationale for intravesical N-trifluoroacetyladriamycin-14-valerate (AD 32): a preclinical study
CN1901906B (zh) 治疗套细胞淋巴瘤的cci-779
CN101257921A (zh) 使用卡奇霉素-抗体偶联物与zosuquidar的组合治疗癌症患者
JP2009501707A (ja) 癌の処置のためのゾスキダル、ダウノルビシン、およびシタラビン
US12226433B2 (en) Treatment of irritable bowel syndrome with molybdenum
WO2026076018A1 (en) Injectable formulations of parp inhibitors and uses thereof
CN122074045A (zh) 紫杉醇缀合化合物、组合物及其使用方法
HK40000014B (en) Clincal regimen for treating myelodysplastic syndrome with phosphatase inhibitor
JP2009500416A (ja) カリケアマイシン−抗体複合体をゾスキダルと組み合わせて用いる癌患者の処置
MX2008000226A (en) Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
CN103054876A (zh) 一种组合物及其产品和制药用途
WO2009111555A1 (en) Combination treatment for bladder cancer comprisining valrubicin and trospium chloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired